A Cayman Islands exempted company delivering superior risk-adjusted returns through disciplined, research-driven global investment — led by Founder & Director Wu Jiaqiang（吴佳强）, with directors Wu Jiaqiang（吴佳强）& Xu Zhe（许哲）.
Backing technology-driven healthcare and life-science companies with proprietary barriers — from high-end medical devices to CGT enabling equipment.
Explore → No. 02An options-based multi-strategy approach treating volatility as an independent asset class, with capital preservation as the first principle.
Explore → No. 03Upgrading from managing strategies to building a platform for long-term capital allocation, anchored in Hong Kong's primary markets.
Explore →Targeting technology-driven healthcare and life-science companies with proprietary barriers and clear import-substitution or industrialization potential — spanning medical devices, cell & gene therapy (CGT) enabling equipment, advanced materials, and biomedical imaging.
A three-engine options-based structure treating volatility as an independent asset class — designed to capture index upside while remaining antifragile during market crashes. The strategy does not rely on market timing; it uses structural convexity to turn extreme volatility into opportunity.
Fully invested in Nasdaq-100 leaders — the engine of the AI revolution. Maintains >100% participation in NDX upside through systematic long positions.
Selling short-dated put options to collect premiums continuously. Premium income funds protective positions and reduces effective holding cost — whether exercised or not.
Deep OTM calls hedge against "missing the rally"; ultra-long-dated ITM puts provide crash protection with near-zero net cost (forward premium offsets option premium). The structure profits from both surges and collapses.
+87% cumulative return since inception (Jun 2024) vs NDX +53.3%. In the April 2025 tariff shock — when NDX dropped −17% — the strategy returned +11.13%, then rose to +17.88% during the rebound without giving back crash gains. This is bidirectional convexity: rare protection that does not surrender its profits when markets recover.
The portfolio is structurally positioned to benefit from extreme volatility — not merely survive it.
Volatility is harvested as an independent source of return via timing-based position sizing on the volatility curve.
Instead of predicting markets, we build structures that work across regimes — bull, bear, and panic.
| Entity | Role | Status |
|---|---|---|
| Peach Blossom Capital | Existing options-based multi-strategy fund with a proven track record. | Operating · Outperforming Benchmark |
| Bonanza Investment | New anchor-investment platform focused on HK IPOs. | Launched |
| Cayman Islands Entity | Legal holding vehicle for the anchor business. | Incorporation Starting |
Leverage Peach Blossom Capital's proven investment capability as the foundation; via Bonanza Investment + the Cayman entity, upgrade from "managing strategies" to "building a platform for long-term capital allocation."
Subscribe as an anchor investor at the offer price to provide price support and market confidence.
Beyond pure financial investment — deeper, relationship-driven deals across global (especially China–Hong Kong) markets.
Differentiated opportunities at the intersection of public and private markets; pre-IPO names already tracked become priority anchor targets at listing.
High technical barriers and deep domain knowledge, consistent with the existing portfolio.
Launched Bonanza Investment; advancing Cayman entity incorporation as the legal vehicle for the anchor business.
TowardPi (图湃医疗) — deep involvement, key milestone in latest pre-IPO round. CellBri (赛桥生物) — full-cycle support on positioning, investor comms and financing; funding round to be announced.
Peach Blossom Capital's options-based method outperformed major indices last quarter (see Section 02).
Originator innovation from the NTCP receptor discovery (Li Wenhui, 2012) → Libevitamab（立贝韦塔单抗）, the world's first antibody drug for viral hepatitis and China's first HDV treatment — approved January 2026, first prescription in March.
Focused on liver disease with oncology as risk-balancing "capability spillover"; "no-man's-land" originator innovation; counter-cyclical support from Beijing's biomedical industry fund.